 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company's Chief Medical...

Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023

electroCore, Inc. (NASDAQ:ECOR  Free Report)  HC Wainwright reduced their FY2023 earnings per share (EPS) estimates for electroCore in a report released on Thursday, November 9th. HC...

electroCore, Inc. (NASDAQ:ECOR) to Post FY2023 Earnings of ($3.50) Per Share, HC Wainwright Forecasts

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

electroCore price target raised to $11 from $10 at H.C. Wainwright

Ladenburg Thalmann & Co. analyst Jeffrey Cohen reiterated a Buy rating on Electrocore (ECOR Research Report) today and set a price target of $26...

Electrocore's Strong Q3 Results and Promising Future Prospects Justify 'Buy' Rating: A Comprehensive Analysis

electroCore, Inc. (ECOR) Q3 2023 Earnings Call Transcript...

electroCore, Inc. (ECOR) Q3 2023 Earnings Call Transcript

electroCore (NASDAQ:ECOR  Get Free Report) had its price target boosted by stock analysts at HC Wainwright from $10.00 to $11.00 in a note issued to investors on Thursday, Benzinga reports...

electroCore (NASDAQ:ECOR) Given New $11.00 Price Target at HC Wainwright

Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5 million...

electroCore Announces Third Quarter 2023 Financial Results

ROCKAWAY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger...

electroCore to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia
 FIGURE 1

 Primary Endpoint (n=35...

Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting

electroCore announces extension of gammaCore device listing in NHS Supply Chain

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ.

Watchers	9,371
52-Wk Low	$3.10
52-Wk High	$7.50

Market Cap	$35.05M
Volume (M)	15,378.00
52-Wk High	$7.50
52-Wk Low	$3.10

ECOR ElectroCore Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community